Breaking News

You are here » Indian-Commodity  :  Top News  :  USFDA inspects Alkem Laboratories' Bioequivalence facility at Taloja

15-Jul2017

USFDA inspects Alkem Laboratories' Bioequivalence facility at Taloja

The US Food and Drug Administration (USFDA) has conducted an inspection at Alkem Laboratories' Bioequivalence facility located at Taloja in state of Maharashtra from July 10, 2017 to July 14, 2017. At the end of the inspection, no Form 483 was issued.

Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.



Related News

View all news

Gold futures end higher on Tuesday

Gold futures finished higher on Tuesday, marking biggest single-session percentage rise since November, as investors increased bullion investments amid potential progress on Brexit and trade talks between......

Jeera futures trade lower on NCDEX

Jeera futures traded lower on NCDEX, as speculators reduced exposure on account of reduced export demand in the physical market. Moreover, expectation of higher production due to adequate availability......

Copper futures end higher on weaker dollar

Copper futures ended higher on Tuesday due to a weaker US dollar and hopes that the United States and China would forge a trade deal. A new round of talks between the United States and top metals consumer......

Top News

View all news

Tata Motors signs LTS agreement with its employees

Tata Motors has signed a long-term wage settlement (LTS) agreement with its employees. Under the agreement, workmen will get a wage rise of Rs 9,000 per month along with other incentives based on performance.......

Canara Bank invites bids from merchant bankers to manage its $350-500 million MTN issue: Report

Canara Bank has reportedly invited bids from merchant bankers to manage its $350-500 million issue of senior unsecured/tier-II capital bonds under its medium-term note (MTN) programme. The issue size may......

Alembic Pharma gets USFDA's nod for Acetazolamide Extended-Release Capsules

Alembic Pharmaceuticals (Alembic) has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Acetazolamide Extended-Release Capsules, 500......